Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 201–300 of 1,000
Lee, M., Hills, M., Conomos, D., Stutz, M. D., Dagg, R. A., Lau, L. M. S., Reddel, R. R., & Pickett, H. A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1117 · Cited by 116
“of telomeres (ALT) pathway (10), which involves homologous recombination-mediated telomere extension using”
BackgroundSelf-citationJiang, W.-Q., Zh, Z., Henson, J. D., & Reddel, R. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210260 · Cited by 133
“Most cancers utilize telomerase (Greider and Blackburn, 1985) for this purpose, but a significant minority utilize an alternative lengthening of telomeres (ALT) mechanism (Bryan et al., 1995, 1997).”
BackgroundSelf-citationNabetani, A., & Ishikawa, F. (2011) · Journal of Biochemistry · doi:10.1093/jb/mvq119 · Cited by 113
Protein phase separation and its role in tumorigenesis
Jiang, S., Fagman, J. B., Chen, C., Alberti, S., & Liu, B. (2020) · eLife · doi:10.7554/elife.60264 · Cited by 126
Nitric oxide and endothelial cellular senescence
Hayashi, T., Yano, K., Matsui‐Hirai, H., Yokoo, H., Hattori, Y., & Iguchi, A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.002 · Cited by 128
Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids
Perrem, K., Bryan, T. M., Englezou, A., Hackl, T., Moy, E. L., & Reddel, R. R. (1999) · Oncogene · doi:10.1038/sj.onc.1202752 · Cited by 131
“Some immortalized cell lines, however, do not have any detectable telomerase activity but have a highly characteristic pattern of telomere lengths that range from very short to abnormally long (Murnane et al., 1994; Bryan et al., 1995, 1997).”
BackgroundSelf-citationNuclear PARPs and genome integrity
Azarm, K., & Smith, S. H. (2020) · Genes & Development · doi:10.1101/gad.334730.119 · Cited by 123
“Telomere resolution in ALT cancer cells Persistent telomere cohesion in mitosis has also been observed to occur naturally in cancer cells that use alternative lengthening of telomeres (ALT), a recombination-based mechanism of telomere maintenance (Bryan et al. 1997; Ramamoorthy and Smith 2015; Sobinoff and Pickett 201…”
BackgroundCuthbert, A. P., Bond, J., Trott, D. A., Gill, S., Broni, J., Marriott, A., Khoudoli, G., Parkinson, E. K., Cooper, C. S., & Newbold, R. F. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.37 · Cited by 114
“Alternative pathways of human telomere maintenance (possibly recombinational) have been implicated in a number of immortal cell lines, including a subset of simian virus 40 (SV40) large Tantigen-immortalized diploid fibroblasts (43) and a small proportion of human tumor cell lines ( 44 ).”
BackgroundTelomere Length Dynamics and DNA Damage Responses Associated with Long-Duration Spaceflight
Luxton, J. J., McKenna, M. J., Lewis, A. M., Taylor, L. E., George, K. A., Dixit, S. M., Moniz, M., Benegas, W., MacKay, M. J., Mozsary, C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108457 · Cited by 120
Telomere Replication: Solving Multiple End Replication Problems
Bonnell, E., Pasquier, E., & Wellinger, R. J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668171 · Cited by 126
Telomere dysfunction alters the chemotherapeutic profile of transformed cells
Lee, K.-H., Rudolph, K. L., Ju, Y.-J., Greenberg, R. A., Cannizzaro, L., Chin, L., Weiler, S. R., & DePinho, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051629198 · Cited by 111
Matarredona, E. R., & Pastor, Á. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00779 · Cited by 121
“Additionally, some cancer cells use a telomerase-independent mechanism to elongate their telomeres (72).”
BackgroundRole of Telomerase in Cell Senescence and Oncogenesis
Urquidi, V., Tarin, D., & Goodison, S. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.65 · Cited by 123
p16INK4a and the control of cellular proliferative life span
Huschtscha, L. I. (1999) · Carcinogenesis · doi:10.1093/carcin/20.6.921 · Cited by 111
Telomeres in aging and disease: lessons from zebrafish
Carneiro, M. C., de Castro, I. P., & Ferreira, M. G. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025130 · Cited by 106
“The (yet undemonstrated) explanation is that tert − / − zebrafish tumours are efficient in engaging mechanisms of alternative lengthening of telomeres (ALT) (Bryan et al., 1997).”
Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres
Dagg, R. A., Pickett, H. A., Neumann, A. A., Napier, C. E., Henson, J. D., Teber, E. T., Arthur, J. W., Reynolds, C. P., Murray, J., Haber, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.087 · Cited by 110
Self-citationAlternative Lengthening of Telomeres in Human Cells
Reddel, R. R., Bryan, T. M., Colgin, L. M., Perrem, K. T., & Yeager, T. R. (2001) · Radiation Research · doi:10.1667/0033-7587(2001)155[0194:alotih]2.0.co;2 · Cited by 110
“ALT also occurs frequently in Li–Fraumeni syndrome (LFS) immortal cell lines ( 4 ).”
BackgroundSelf-citationTerahertz Photons Inhibit Cancer Cells Long Term by Suppressing Nano Telomerase Activity
Yin, J., Wu, K., Yu, Y., Zhong, Y., Song, Z., Chang, C., & Liu, G. (2024) · ACS Nano · doi:10.1021/acsnano.3c09216 · Cited by 112
Telomerase Expression Predicts Unfavorable Outcome in Osteosarcoma
Sanders, R. P., Drissi, R., Billups, C. A., Daw, N. C., Valentine, M. B., & Dome, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.043 · Cited by 122
Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells
Ramamoorthy, M., & Smith, S. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.003 · Cited by 100
“The remaining 10% to 15% of cancers activate ALT (alternative lengthening of telomeres) a recombination-basedmechanism that extends telomere repeats using a telomeric DNA template (Bryan et al., 1997; Henson and Reddel, 2010).”
A balance between elongation and trimming regulates telomere stability in stem cells
Rivera, T., Haggblom, C., Cosconati, S., & Karlseder, J. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3335 · Cited by 115
Non-canonical Roles of Telomerase: Unraveling the Imbroglio
Ségal-Bendirdjian, E., & Géli, V. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00332 · Cited by 113
Yamada, M., Hayatsu, N., Matsuura, A., & Ishikawa, F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33360 · Cited by 123
Mammalian telomeres and telomerase: why they matter for cancer and aging
Blasco, M. A. (2003) · European Journal of Cell Biology · doi:10.1078/0171-9335-00335 · Cited by 125
Telomere Length Dynamics in Telomerase-Positive Immortal Human Cell Populations
Bryan, T. M., Englezou, A., Dunham, M. A., & Reddel, R. R. (1998) · Experimental Cell Research · doi:10.1006/excr.1997.3907 · Cited by 115
Self-citationRegulation of Recombination and Genomic Maintenance
Heyer, W. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016501 · Cited by 120
“Of particular interest is the involvement of HR in the telomerase-independent maintenance of telomeres, termed “alternative lengthening of telomeres” (ALT), which maintains telomeres in a subset of human cancers (Bryan et al. 1997).”
BackgroundRegulation of Telomerase and Telomeres: Human Tumor Viruses Take Control
Bellon, M., & Nicot, C. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm269 · Cited by 104
Nuclear-Receptor-Mediated Telomere Insertion Leads to Genome Instability in ALT Cancers
Marzec, P., Armenise, C., Pérot, G., Roumelioti, F., Basyuk, E. I., Gagos, S., Chibon, F., & Déjardin, J. (2015) · Cell · doi:10.1016/j.cell.2015.01.044 · Cited by 110
“However, in a subset of tumors,mostly sarcomas, telomeres aremaintained by a recombination/amplification mechanism termed alternative lengthening of telomeres (ALT) (Bryan et al., 1997).”
The functional roles of PML nuclear bodies in genome maintenance
Chang, H. R., Munkhjargal, A., Kim, M.-J., Park, S. Y., Jung, E. Y., Ryu, J., Yang, Y. D., Lim, J., & Kim, Y. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.05.002 · Cited by 114
“When using ALT-positive cells in PML research, one must consider the possibility that large portion of the factors found at the telomeres might be independent of PML-NBs.”
BackgroundInfluentialReplication fork regression in repetitive DNAs
Fouché, N., Özgür, S., Roy, D., & Griffith, J. D. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl757 · Cited by 98
Boeck, G. D., Forsyth, R. G., Praet, M. M., & Hogendoorn, P. C. W. (2009) · The Journal of Pathology · doi:10.1002/path.2500 · Cited by 118
“Human cancers and some human somatic cells, such as stem cells, germ cells and activated lymphocytes, are able to maintain and/or extend their telomere lengths by two independent mechanisms: synthesis of telomere DNA by the holo-enzyme telomerase [19], or homologous recombination of telomeres by an alternative telomer…”
BackgroundInfluentialOpitz, O. G., Suliman, Y., Hahn, W. C., Harada, H., Blum, H. E., & Rustgi, A. K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11909 · Cited by 99
“Although most immortal cell lines and human tumors are believed to maintain telomere length through activation of telomerase, 10%–15% of tumors (39) and up to 40% of SV40-immortalized cell lines lack detectable telomerase (40).”
BackgroundRecombination in telomere-length maintenance
Kass-Eisler, A., & Greider, C. W. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01557-7 · Cited by 114
Normal mammalian cells negatively regulate telomere length by telomere trimming
Pickett, H. A., Henson, J. D., Au, A. Y. M., Neumann, A. A., & Reddel, R. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr402 · Cited by 93
“Cancer cells activate either telomerase or an alternative lengthening of telomeres (ALT) pathway to prevent telomere shortening and thereby achieve immortalization (4,5); however, the level of telomerase activity in normal human somatic tissues is usually insufficient to completely prevent telomere shortening.”
Self-citationCurrent advances in unraveling the function of the Werner syndrome protein
Ozgenc, A. I., & Loeb, L. A. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.03.020 · Cited by 104
Temporal Telomere and DNA Damage Responses in the Space Radiation Environment
Luxton, J. J., McKenna, M. J., Taylor, L. E., George, K. A., Zwart, S. R., Crucian, B. E., Drel, V. R., Garrett-Bakelman, F. E., Mackay, M. J., Butler, D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108435 · Cited by 94
Chromatin Structure in Telomere Dynamics
Galati, A., Micheli, E., & Cacchione, S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00046 · Cited by 107
Use of the Rad51 promoter for targeted anti-cancer therapy
Hine, C., Seluanov, A., & Gorbunova, V. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807990106 · Cited by 97
“Furthermore, while hTERT is overexpressed in the majority of cancer cells, up to 15% of cancer cells do not express it and rely on alternative, recombination-based mechanisms to extend their telomeres, termed alternative lengthening of telomeres (ALT) (43).”
BackgroundZhang, P., Chan, S. L., Fu, W., Mendoza, M., & Mattson, M. P. (2003) · The FASEB Journal · doi:10.1096/fj.02-0603fje · Cited by 96
“Based on these results, we performed site-directed mutagenesis of the RT and 14-3-3 binding regions of TERTm and then overexpressed WT TERT, RTmt, and 14-3-3mt in three human cell lines known to differ in their expression of telomerase components: HeLa cells express both TERT and the telomerase RNA component; GM847 ce…”
MethodKim, S., Bi, X., Czarny-Ratajczak, M., Dai, J., Welsh, D. A., Myers, L., Welsch, M. A., Cherry, K. E., Arnold, J., Poon, L. W., et al. (2012) · Biogerontology · doi:10.1007/s10522-011-9360-5 · Cited by 96
“Telomere length can also be maintained through alternative lengthening mechanisms in the absence of telomerase activity, as described in cancer cells (Bryan et al. 1997; Reddel et al. 2001; Reddel and Bryan 2003).”
Fouladi, B., Sabatier, L., Miller, D., Pottier, G., & Murnane, J. P. (2000) · Neoplasia · doi:10.1038/sj.neo.7900107 · Cited by 96
Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers
Udugama, M., Sanij, E., Voon, H. P. J., Son, J., Hii, L., Henson, J. D., Chan, F. L., Chang, F. T. M., Liu, Y., Pearson, R. B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720391115 · Cited by 94
“ALT is an aberrant DNA recombination mechanism that drives telomere DNA elongation independent of telomerase activity, resulting in enormously long and damaged telomeres (11, 13).”
Telomeres and telomerase as targets for anticancer drug development
Olaussen, K. A., Dubrana, K., Dômont, J., Spano, J., Sabatier, L., & Soria, J. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.007 · Cited by 111
The human Pif1 helicase, a potential Escherichia coli RecD homologue, inhibits telomerase activity
Zhang, D.-H., Zhou, B., Huang, Y., Xu, L., & Zhou, J.-Q. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl029 · Cited by 108
“In humans, each chromosome end bears 5–15 kb of TTAGGG/CCCTAA repeated DNA, which is maintained by telomerase (3) and/or alternative lengthening of telomere (ALT) pathway (2,4).”
BackgroundBRCA1 Inhibition of Telomerase Activity in Cultured Cells
Xiong, J., Fan, S., Meng, Q., Schramm, L., Wang, C., Bouzahza, B., Zhou, J., Zafonte, B. T., Goldberg, I. D., Haddad, B. R., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8668-8690.2003 · Cited by 110
“Alternatively, the telomere maintenance could be due to a telomerase-independent mechanism for the alternative lengthening of telomeres, a process that is often observed in tumor cells (6, 9).”
BackgroundTelomerase: regulation, function and transformation
Dong, C. K., Masutomi, K., & Hahn, W. C. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.12.005 · Cited by 106
Many ways to telomere dysfunction: in vivo studies using mouse models
Goytisolo, F. A., & Blasco, M. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205085 · Cited by 105
“Nevertheless, evidence for ALT in the context of the mouse was obtained from studying the germinal centers of immunized late generation Terc7/7 mice, where it was possible to select splenocyte populations which showed very long telomeres (Herrera et al., 2000).”
BackgroundInfluentialWRN at telomeres: implications for aging and cancer
Multani, A. S., & Chang, S. (2007) · Journal of Cell Science · doi:10.1242/jcs.03397 · Cited by 95
“This increased incidence of mesenchymal cancers is intriguing in light of observations indicating that many human sarcomas maintain telomere lengths by the ALT pathway (Bryan et al., 1995; Bryan et al., 1997) (reviewed by Henson et al., 2002).”
BackgroundVilla, R., Folini, M., Lualdi, S., Veronese, S. M., Daidone, M. G., & Zaffaroni, N. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01540-4 · Cited by 102
Telomere length: how the length makes a difference
Lulkiewicz, M., Bajsert, J., Kopczynski, P., Barczak, W., & Rubis, B. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05551-y · Cited by 89
“The fact is that aging is accompanied by telomere attrition, although its rate is highly heterogeneous between individuals, different types of cells but also different chromosomes [22].”
BackgroundThe significance of telomerase activation and cellular immortalization in human cancer
Newbold, R. F. (2002) · Mutagenesis · doi:10.1093/mutage/17.6.539 · Cited by 100
“In human tumours and tumour-derived cell lines, ALT was identified in ~7% of samples assayed in each case (Bryan et al., 1997).”
BackgroundFujita, T., Asano, Y., Ohtsuka, J., Takada, Y. K., Saito, K., Ohki, R., & Fujii, H. (2013) · Scientific Reports · doi:10.1038/srep03171 · Cited by 100
Release of Telomeric DNA from Chromosomes in Immortal Human Cells Lacking Telomerase Activity
Ogino, H., Nakabayashi, K., Suzuki, M., Takahashi, E., Fujii, M., Suzuki, T., & Ayusawa, D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8875 · Cited by 109
Osterwald, S., Deeg, K. I., Chung, I., Parisotto, D., Wörz, S., Rohr, K., Erfle, H., & Rippe, K. (2015) · Journal of Cell Science · doi:10.1242/jcs.148296 · Cited by 92
MacKenzie, K. L., Franco, S., May, C., Sadelain, M., & Moore, M. A. S. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4982 · Cited by 92
Telomeres: Implications for Cancer Development
Bernal, A., & Tusell, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010294 · Cited by 101
“This supports the notion that approximately 80–90% of human cancers express telomerase and the remainder activate ALT-recombination-based mechanisms to cap chromosome ends [67,172].”
BackgroundPan-cancer analysis identifies telomerase-associated signatures and cancer subtypes
Luo, Z., Wang, W., Li, F., Songyang, Z., Feng, X., Xin, C., Dai, Z., & Xiong, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1035-x · Cited by 99
Repair of DNA Breaks by Break-Induced Replication
Kockler, Z. W., Osia, B., Lee, R. H. C., Musmaker, K., & Malkova, A. (2021) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-081420-095551 · Cited by 95
Kamranvar, S. A., & Masucci, M. G. (2011) · Leukemia · doi:10.1038/leu.2011.35 · Cited by 98
Alternative lengthening of telomeres: remodeling the telomere architecture
Conomos, D., Pickett, H. A., & Reddel, R. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00027 · Cited by 106
Self-citationTelomerase Can Inhibit the Recombination-based Pathway of Telomere Maintenance in Human Cells
Ford, L. P., Zou, Y., Pongracz, K., Gryaznov, S. M., Shay, J. W., & Wright, W. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104469200 · Cited by 96
Telomere dynamic in humans and animals: Review and perspectives in environmental toxicology
Louzon, M., Cœurdassier, M., Gimbert, F., Pauget, B., & de Vaufleury, A. (2019) · Environment International · doi:10.1016/j.envint.2019.105025 · Cited by 100
SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance
Panier, S., Maric, M., Hewitt, G., Mason‐Osann, E., Gali, H., Dai, A., Labadorf, A. T., Guervilly, J.-H., Ruis, P., Segura‐Bayona, S., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.010 · Cited by 95
McDonald, K. L., McDonnell, J., Muntoni, A., Henson, J. D., Hegi, M. E., von Deimling, A., Wheeler, H., Cook, R. J., Biggs, M. T., Little, N., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e576cf · Cited by 97
“Tumors that deregulate proliferation using a telomerase-independent telomere-length maintenance mechanism called alternative lengthening of telomeres (ALTs) are less common (6).”
BackgroundSelf-citationALT Positivity in Human Cancers: Prevalence and Clinical Insights
MacKenzie, D., Watters, A. K., To, J. T., Young, M. W., Muratori, J., Wilkoff, M. H., Abraham, R. G., Plummer, M. M., & Zhang, D. (2021) · Cancers · doi:10.3390/cancers13102384 · Cited by 100
Telomere dysfunction in aging and cancer
Gilley, D. P., Tanaka, H., & Herbert, B. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.09.003 · Cited by 97
Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
Mo, Y., Gan, Y., Song, S., Johnston, J. S., Xiao, X., Wientjes, M. G., & Au, J. L. ‐. (2003) · PubMed · Cited by 90
Grobelny, J. V., Kulp-McEliece, M., & Broccoli, D. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1953 · Cited by 107
“However, a subset of tumors and immortal cell lines utilize a telomerase-independent mechanism, termed alternative lengthening of telomeres (ALT), to maintain telomeric DNA (10,11) and thereby circumvent the telomere length-dependent limitation on proliferation.”
BackgroundRole of TERRA in the regulation of telomere length
Wang, C., Zhao, L., & Lu, S. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10528 · Cited by 89
“ALT occurs in approximately 10–15% of human cancer cells [11-13], in which telomere elongation occurs in ALT-related PML bodies (APBs), a specific class of promyelocytic Ivyspring”
BackgroundAbdul‐Ghani, R., Ohana, P., Matouk, I., Ayesh, S. K., Ayesh, B. M., Laster, M., Bibi, O., Giladi, H., Molnar-Kimber, K. L., Sughayer, M. A., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0196 · Cited by 98
Krüppel-Like Transcription Factor 4 Contributes to Maintenance of Telomerase Activity in Stem Cells
Wong, C., Hou, P.-S., Tseng, S., Chien, C. L., Wu, K.-J., Chen, H., Ho, H., Kyo, S., & Teng, S. (2010) · Stem Cells · doi:10.1002/stem.477 · Cited by 96
The telomere length dynamic and methods of its assessment
Lin, K.-W., & Yan, J. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00395.x · Cited by 85
“Some tumor cells do not express telomerase activity; the stabilization of telomeres is maintained by telomeraseindependent mechanism, an 'alternative lengthening of telomeres' (ALT), when the G-strand overhang invade the loop structure and act as the template for its elongation [26, 27].”
BackgroundMontgomery, E. A., Argani, P., Hicks, J. L., Marzo, A. M. D., & Meeker, A. K. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63710-8 · Cited by 98
Otterlei, M., Bruheim, P., Ahn, B., Bussen, W., Karmakar, P., Baynton, K., & Bohr, V. A. (2006) · Journal of Cell Science · doi:10.1242/jcs.03291 · Cited by 85
“ALT pathways have also been detected in a number of immortalized human cell lines lacking telomerase (Bryan et al., 1997; Colgin and Reddel, 1999), and ALT cells contain ALT-associated PML bodies consisting of promyelocytic leukaemia protein (PML), telomeric DNA, the telomere binding proteins TRF1 and TRF2, the RAD ho…”
BackgroundMammalian 5′ C-Rich Telomeric Overhangs Are a Mark of Recombination-Dependent Telomere Maintenance
Oganesian, L., & Karlseder, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.015 · Cited by 84
p16INK4a as a Second Effector of the Telomere Damage Pathway
Jacobs, J. J. L., & de Lange, T. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2104 · Cited by 87
Detection of alternative lengthening of telomeres by telomere quantitative PCR
Lau, L. M. S., Dagg, R. A., Henson, J. D., Au, A. Y. M., Royds, J. A., & Reddel, R. R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks781 · Cited by 93
Self-citationHu, Y., Shi, G. W., Zhang, L., Li, F., Jiang, Y., Jiang, S., Ma, W., Zhao, Y. B., Songyang, Z., & Huang, J. (2016) · Scientific Reports · doi:10.1038/srep32280 · Cited by 92
Cudré-Mauroux, C., Occhiodoro, T., König, S., Salmon, P., Bernheim, L., & Trono, D. (2003) · Human Gene Therapy · doi:10.1089/104303403322495034 · Cited by 87
“In the contrary of telomerase positive cells, ALT cells have extremely heterogeneous telomere lengths, ranging from very short to extremely long (Bryan et al., 1997).”
InfluentialCdc13 prevents telomere uncapping and Rad50‐dependent homologous recombination
Grandin, N., Damon‐Soubeyrand, C., & Charbonneau, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.21.6127 · Cited by 93
Comprehensive Structure-Function Analysis of the Core Domain of Human Telomerase RNA
Ly, H., Blackburn, E. H., & Parslow, T. G. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.19.6849-6856.2003 · Cited by 85
“component of the human telomerase complex (8), was maintained in Dulbecco’s”
Telomeres and Telomerase: Basic Science Implications for Aging
Ahmed, A., & Tollefsbol, T. O. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49217.x · Cited by 95
Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence?
Pelicci, P. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420750 · Cited by 85
Molecular Oncology of Breast Cancer
Joshi, H. N., & Press, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00022-2 · Cited by 97
Ducrest, A., Amacker, M., Mathieu, Y., Cuthbert, A. P., Trott, D. A., Newbold, R. F., Nabholz, M., & Lingner, J. (2001) · PubMed · Cited by 101
Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends
Hoang, S. M., & O’Sullivan, R. J. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.009 · Cited by 90
Immortalization and Transformation of Human Cells
C. Hahn, W. (2002) · Molecules and Cells · doi:10.1016/s1016-8478(23)15045-x · Cited by 84
Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Soares, P., Lima, J., Preto, A., Castro, P., Vinagre, J., Celestino, R., P. Couto, J., Prazeres, H., Eloy, C., Maximo, V., et al. (2011) · Current Genomics · doi:10.2174/138920211798120853 · Cited by 85
“Some tumours may maintain their telomeres by an alternative mechanism, telomeraseindependent, designated as ALT (alternative lengthening of telomeres), which appears to maintain telomeres through recombination based interchromosomal exchange of sequence information [72-73].”
BackgroundFajkus, P., Peška, V., Sitová, Z., Fulnečková, J., Dvořáčková, M., Gogela, R., Sýkorová, E., Hapala, J., & Fajkus, J. (2015) · The Plant Journal · doi:10.1111/tpj.13115 · Cited by 84
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 91
“In the alternative pathway tumors become immortalized via a recombinationdriven mechanism called alternative lengthening of telomeres (ALT) [21].”
BackgroundInfluentialChoe, W., Budd, M. E., Imamura, O., Hoopes, L. L. M., & Campbell, J. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4202-4217.2002 · Cited by 95
“This is the type of survivor seen in alternative methods of maintaining telomeres (ALT) in mammalian tumor cells (8).”
MethodPathways for maintenance of telomeres and common fragile sites during DNA replication stress
Özer, Ö., & Hickson, I. D. (2018) · Open Biology · doi:10.1098/rsob.180018 · Cited by 89
Baird, D. M., Coleman, J., Rosser, Z. H., & Royle, N. J. (2000) · The American Journal of Human Genetics · doi:10.1086/302721 · Cited by 95
“If short telomeres have an altered chromatin structure, the suppressive chromatin effect on recombination may be lost and the short telomere may become available for elongation by means of recombination-based mechanisms (Bryan et al. 1995; Bryan et al. 1997).”
BackgroundRescue of an hTERT Mutant Defective in Telomere Elongation by Fusion with hPot1
Armbruster, B. N., Linardic, C. M., Veldman, T., Bansal, N. P., Downie, D. L., & Counter, C. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3552-3561.2004 · Cited by 83
“meres (12), were stably infected with pBabepuro-Flag-hPot1 or pBabepuro-Flag-”
BackgroundMethodTherapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 97
Lafferty‐Whyte, K., Cairney, C. J., Will, M., Serakıncı, N., Daidone, M. G., Zaffaroni, N., Bilsland, A. E., & Keith, W. N. (2009) · Oncogene · doi:10.1038/onc.2009.238 · Cited by 82
“, 2006), adrenocortical carcinoma, breast carcinoma, malignant melanoma, lung carcinoma, ovarian carcinoma (Bryan et al., 1997) and renal carcinoma (Mehle et al.”
BackgroundTelomere Maintenance Mechanisms in Cancer: Clinical Implications
Reddel, R. R. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140630101047 · Cited by 97
“Types of tumors where ALT is very common include osteosarcomas, undifferentiated pleomorphic sarcomas, leiomyosarcomas, and grade 2 and 3 astrocytic brain tumors, but ALT is also common in some other types of soft tissue sarcomas, grade 4 astrocytic brain tumors (glioblastomas), and neuroblastomas, and occurs at low f…”
BackgroundMethodInfluentialSelf-citationLee, J. H., Khadka, P., Baek, S. H., & Chung, I. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149831 · Cited by 96
Ford, L. P., Suh, J. M., Wright, W. E., & Shay, J. W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.9084-9091.2000 · Cited by 96
“VA13 cells are simian virus 40 large T antigen immortalized and use a telomerase-independent mechanism to maintain their telomeres (6).”
BackgroundChang, F. T. M., McGhie, J. D., Chan, F. L., Tang, M. C., Anderson, M. A., Mann, J. R., Andy Choo, K. H., & Wong, L. H. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt114 · Cited by 76
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.